Immunocore Holdings plc (IMCR)
IMCR trades on Nasdaq in Health Care, Biotechnology: Biological Products (No Diagnostic Substances). Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price · October 14, 2026
$27.82
-4.20% on the day
Market cap
$1.4B
Small cap
Revenue · 2025
$400.0M
+29.0% on 2024
Net income · 2025
-$35.5M
-8.9% net margin
Price, change, market cap, sector and industry: Nasdaq stock screener, as of October 14, 2026. Revenue: SEC XBRL frames, calendar 2025.
Profile
| Field | Value |
|---|---|
| Ticker | IMCR on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) |
| Country | United Kingdom |
| IPO year | 2021 |
| SEC CIK | 0001671927 |
| SEC industry code | Biological Products, (No Diagnostic Substances) |
| Incorporated in | X0 |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $400.0M |
| Net income | -$35.5M |
| Operating income | -$45.4M |
| Net margin | -8.9% |
| Operating margin | -11.3% |
| Revenue growth | +29.0% |
| Cash | $467.7M |
| Total assets | $1.1B |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 3.6× |
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document 427B7 | 424B7 | 2025-03-17 |
| Latest annual report | 10-K | 2026-02-25 |
| Latest quarterly / interim | 10-Q | 2026-08-06 |
| Latest current report | 8-K | 2026-09-14 |
| Latest proxy | DEF 14A | 2026-04-16 |
Source: SEC EDGAR submissions feed, 279 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -3.8% |
| 1 month | -11.0% |
| 3 months | -18.0% |
| Year to date | -18.5% |
| 1 year | -12.6% |
| From 52-week high | -29.7% |
Source: Yahoo Finance daily closes, last bar 2026-10-14. Computed by Sophia Capital from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Biological Products (No Diagnostic Substances)
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| COAG | Hemab Therapeutics Holdings Inc. | $29.80 | -1.94% | $1.4B |
| MAZE | Maze Therapeutics Inc. | $26.66 | -3.75% | $1.5B |
| INBX | Inhibrx Biosciences Inc. | $87.08 | -3.81% | $1.3B |
| TSHA | Taysha Gene Therapies Inc. | $3.58 | -13.53% | $1.2B |
| VIR | Vir Biotechnology Inc. | $10.61 | -6.11% | $1.8B |
| REPL | Replimune Group Inc. | $12.11 | -7.34% | $1.1B |
| MESO | Mesoblast Limited | $13.89 | -2.63% | $1.8B |
| VOR | Vor Biopharma Inc. | $19.06 | -3.74% | $1.1B |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier